Medication Management for Fibroids, Endometriosis, and Adenomyosis

First-Line Recommendations

• The American College of Radiology recommends initiating a levonorgestrel-releasing intrauterine device (LNG-IUD 20 μg/d) as first-line therapy for patients with concurrent fibroids, endometriosis, and adenomyosis, which reduces menstrual blood loss by 71-95% and provides superior symptom control compared to combined oral contraceptives 1
• The LNG-IUD is clinically favored due to its local mechanism of action, lower systemic hormone levels, long duration after placement, and user independence, as recommended by the American College of Radiology 2, 3

Medical Management Hierarchy

• A recent randomized controlled trial demonstrated significant improvement in both pain and bleeding in women with adenomyosis treated with LNG-IUD versus combined oral contraceptives, according to the American College of Radiology 3
• Efficacy of LNG-IUD is comparable to endometrial ablation with 71-95% reduction in menstrual blood loss, as stated by the American College of Radiology 1
• Combined oral contraceptives reduce painful and heavy menstrual bleeding in randomized controlled trials, though less effective than LNG-IUD, as reported by the American College of Radiology 1, 2, 3
• Oral GnRH antagonists (elagolix, linzagolix, relugolix) are highly effective for heavy menstrual bleeding, with a reduction in fibroid volume by 18-30%, according to the American College of Radiology 4, 5, 6
• Combination treatment with low-dose estrogen and progestin add-back therapy is mandatory to mitigate hypoestrogenic effects when using GnRH antagonists, as recommended by the American College of Radiology 1, 5, 6

Nonhormonal Medical Options

• Tranexamic acid provides significant reduction in menstrual blood loss as a nonhormonal alternative, ideal for patients who cannot or prefer not to use hormonal therapy, according to the American College of Radiology 1, 4, 5, 6
• NSAIDs reduce menstrual blood loss and bleeding symptoms, but should be avoided in women with cardiovascular disease, as recommended by the American College of Radiology 1, 4, 5, 6

Interventional Options

• Uterine artery embolization (UAE) provides short-term symptom improvement in 94% and long-term improvement in 85% of patients, with symptom control and quality of life improvement maintained up to 7 years, according to the American College of Radiology 1, 3, 4, 6
• Endometrial ablation offers greater long-term efficacy than oral medical treatment and reduces pregnancy risk while managing bleeding, as stated by the American College of Radiology 1

Surgical Management

• Hysterectomy provides definitive resolution of all fibroid-related symptoms with patient satisfaction rates up to 90%, and is recommended when medical and interventional therapies fail, according to the American College of Radiology 1, 3, 5, 6

Critical Pitfalls and Caveats

• No medical therapy eradicates adenomyosis lesions; all provide only temporary symptom relief with rapid recurrence after discontinuation, as stated by the American College of Radiology 1
• Medical therapies will not treat bulk symptoms associated with fibroids, according to the American College of Radiology 2, 3, 4

Uterine Artery Embolization for Adenomyosis

Interventional Options

• Long-term symptomatic relief (median follow-up 27.9 months) in patients with pure adenomyosis or adenomyosis with coexistent leiomyomas ranges from 65% to 82% after uterine artery embolization (UAE), according to the American College of Radiology 7
• More recent retrospective studies (median follow-up ranging from 24 to 65 months) report symptomatic control in 73% to 88% of patients after UAE, as reported by the American College of Radiology 7

Fertility‑Preserving Interventional Options for Adenomyosis

Uterine Artery Embolization (UAE)

• Limited evidence supports UAE as a fertility‑preserving treatment for adenomyosis; comprehensive pregnancy outcome data are lacking, so patients should be counseled that UAE is not a standard option for preserving fertility – American College of Radiology (low‑quality evidence) 8
• A retrospective cohort reported spontaneous pregnancy in 29.5 % of women at 1 year and 40.1 % at 2 years after UAE, with an 81 % live‑birth rate; however, the cohort included patients with both uterine fibroids and adenomyosis, limiting the applicability to adenomyosis‑only cases – American College of Radiology (Level III evidence) 8

MR‑Guided Focused Ultrasound (MRgFUS)

• Evidence for MRgFUS in adenomyosis is confined to isolated case reports, and a randomized trial was terminated because of insufficient enrollment, indicating a lack of robust data to support its use for fertility preservation – American College of Radiology (very low‑quality evidence) 8

GnRH Agonists and Antagonists for Adenomyosis: Indications, Efficacy, and Safety

Indications and Treatment Position

• GnRH agonists (e.g., leuprolide acetate) and oral GnRH antagonists (e.g., elagolix, linzagolix, relugolix) are recommended as third‑line medical therapy for premenopausal women with symptomatic adenomyosis after failure of levonorgestrel‑releasing IUD and oral hormonal options. 9

Analgesic Efficacy

• In women with adenomyosis, GnRH agonists provide pain relief comparable to danazol for a treatment duration of 3–6 months. 10

Mandatory Add‑Back Therapy

• Low‑dose estrogen‑progestin add‑back therapy must be given concurrently with GnRH agonists or antagonists to prevent bone mineral loss and mitigate hypo‑estrogenic side effects (headaches, hot flushes, hypertension). [9][10]
• The same add‑back regimen eliminates GnRH‑induced bone loss without reducing analgesic efficacy. 10

Fertility Considerations

• GnRH therapy suppresses fertility, making it inappropriate for women actively attempting conception. [9][11]

Symptom Recurrence After Discontinuation

• Up to 44 % of women experience recurrence of adenomyosis‑related symptoms within one year after stopping GnRH treatment. 10

Limitations of Medical Therapy

• No medical therapy, including GnRH agonists or antagonists, eradicates adenomyotic lesions; all provide only temporary symptom relief. 10

Non‑Hormonal Alternatives

• Tranexamic acid significantly reduces menstrual blood loss and is a viable non‑hormonal option for adenomyosis patients. 9
• NSAIDs decrease menstrual bleeding and related symptoms but should be avoided in patients with cardiovascular disease. [9][11]